FDA Recall of Semaglutide-Glycine-Cyanocobalamin Injectable Due to Sterility Concerns
Areazine synthesizes this FDA recall directly from FDA's official public data feed. See our methodology for full source attribution and refresh cadence.
PAYLESS COMPOUNDERS, LLC is recalling 91 vials of Semaglutide-Glycine-Cyanocobalamin Injectable because of a lack of assurance of sterility, affecting products distributed in Oregon.
What this FDA recall tells you, and what most readers miss
This notice was issued by FDA on May 3, 2026 and geographically references Oregon, United States. Its severity classification of "medium" signals how the issuing agency weighs the risk of harm if no action is taken - "critical" and "high" tier alerts typically carry direct consumer actions, while "medium" and "low" tend toward informational guidance or monitoring advisories. The category it belongs to - FDA Recalls - determines the consumer-protection framework behind it, which shapes what remedies (refunds, replacements, repairs, or the recall itself) are available to affected consumers and which agency holds statutory responsibility for enforcement.
Most readers skim a notice like this, check whether they are personally affected, and move on. The more useful lens is to verify its scope, source, and timestamp, then compare related notices without assuming that one record proves a broader trend.
Areazine pairs this record with the original agency URL so you can check the primary source before acting. Its related labels are recall, product-safety, fda, Drugs.
What Happened
PAYLESS COMPOUNDERS, LLC is recalling Semaglutide-Glycine-Cyanocobalamin Injectable due to a lack of assurance of sterility.
Which Products Are Affected
The affected products are Semaglutide-Glycine-Cyanocobalamin Injectable, 2.5 mg, 5 mg, 1 MG/ML, 0.5 mL vials, Rx only, from Northwest Compounders, Beaverton, OR. A total of 91 vials are involved, with Lot Number 01-27-2026@14S.5. This recall pertains to products distributed in Oregon.
What You Should Do
Consumers who have received a letter from the firm should follow the instructions provided in that notification regarding the product.
Why This Matters
This recall addresses potential risks associated with pharmaceutical products, helping to maintain public health standards by ensuring sterility in medications.
Source
This recall is announced by the FDA. For more information, reference recall number D-0471-2026 on the FDA website.
Original source: FDA Official Notice ↗
Related FDA Recalls
All FDA Recalls →Nationwide notices with similar length or severity timing 8
Two Areazine-derived peer sets for this FDA recall: nearest notices by body length and by same severity near the same agency date. Peers come from other categories so they are not the same-feed Related list above.
Similar body length
Nearest notices by article body length (925 characters here).
Similar severity timing
Same severity (medium) notices issued closest in time to May 3, 2026.
Frequently Asked Questions
Common questions about this FDA recall.